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Introduction
Breast cancer is a hormone-related cancer, as are cancers
of the endometrium, ovary, and prostate [1]. Although the
molecular mechanisms involved in initiation and progres-
sion are poorly understood, there is evidence that extracel-
lular levels of androgens are associated with the
A49T = codon 49 alanine to threonine substitution; BMI = body mass index; bp = base pairs; CI = confidence interval; L/L = leucine/leucine; OR =
odds ratio; PCR = polymerase chain reaction; SRD5A2 = steroid 5α-reductase type II; V89L = codon 89 valine to leucine substitution; V/L =
valine/leucine; V/V = valine/valine.
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Abstract
Background: Breast cancer is hormone related, as are cancers of the endometrium, ovary, and
prostate. Several studies have suggested that higher extracellular levels of androgens are associated
with breast cancer risk, while biological evidence indicates that androgens are protective. The codon
49 alanine to threonine substitution (A49T), codon 89 valine to leucine substitution (V89L) and TA
repeat polymorphisms of the steroid 5α-reductase type II (SRD5A2) gene are considered functional
with respect to enzyme activity converting testosterone into dihydrotestosterone. To test the
hypothesis that these three polymorphisms are associated with risk of breast cancer, a case–control
study was conducted with patients of Aichi Cancer Center Hospital.
Methods: The cases were 237 patients histologically diagnosed with breast cancer, and the controls
were 185 noncancer outpatients. DNA from peripheral blood was genotyped by PCR methods.
Results: The threonine allele of A49T was not found in our subjects. Compared with the V/V genotype
of V89L, the L/L genotype was associated with a decreased risk (crude odds ratio [OR] = 0.61, 95%
confidence interval [CI] = 0.36–1.05). This was also the case for the TA(9/9) genotype, with an OR of
0.58 (95% CI = 0.13–2.63) relative to TA(0/0). Among women with the TA(0/0) genotype, however,
the OR for the L/L genotype was 0.46 (95% CI = 0.24–0.88) compared with the V/V genotype, and
those with the V/V and TA(0/0) genotypes had the highest risk. The haplotype with the L and TA(9)
repeat alleles was not found.
Conclusion: This study is the first to our knowledge focusing on Japanese women, suggesting that
SRD5A2 polymorphisms might have an association with breast cancer risk. Further large-sample studies
will be required to confirm the association and to assess any interactions with environmental factors.
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development of breast cancer [2,3]. Nested case–control
studies have shown that increased circulating levels of
testosterone elevate the risk of breast cancer [4–6].
Experimental studies suggest, however, that androgens
exert a potent antiproliferative effect on the growth of
several hormone-sensitive human breast cancer cells
under both basal and estrogen-induced incubation condi-
tions in vitro [7], as well as in vivo, using ZR-75-1 human
breast cancer cells in nude mice [8]. Androgens have
been used for the treatment of breast cancer [9,10].
Steroid 5α-reductase converts testosterone to the meta-
bolically more active dihydrotestosterone, which has two
isoforms; type I expressed in liver, skin and scalp by
SRD5A1 located on chromosome 5; and type II
expressed in prostate by SRD5A2 on chromosome 2. In
human breast invasive ductal carcinomas, both type I
(58% of 60 cases) and type II (15% of 60 cases) are
reportedly expressed [11].
The SRD5A2 gene consists of five exons and four introns,
and encodes a 254 amino acid protein [12]. Several
single nucleotide polymorphisms have been reported in
the five exons [13]. However, only two of these polymor-
phisms (A49T and V89L), along with the variable number
of dinucleotide TA repeat polymorphisms in the 3′ untrans-
lated region, have been examined concerning risk and
prognosis of cancers.
The V89L polymorphism that substitutes leucine for valine
at codon 89 is reported to reduce almost 30% of
androstanediol glucuronide, a serum marker of 5α-reduc-
tase activity, among Asians [14]. Among Caucasian men, a
10% insignificantly lower androstanediol glucuronide level
was observed for individuals with the L/L genotype [15].
The TA repeat polymorphism reportedly has 10 alleles with
0, 8, 9, 10, 17, 18, 19, 20, 21, and 22 repeats, among
which the 0-repeat allele (designated TA(0)) and the 9-
repeat allele (designated TA(9)) are common. The alleles
with more than 10 repeats were found exclusively in African-
Americans, the highest risk ethnic group of prostate cancer
[16]. No significant difference in serum androstanediol glu-
curonide level was reported between the TA(0/0) and
TA(0/9) genotypes among the Chinese [17].
In the A49T polymorphism that substitutes threonine for
alanine at codon 49, the T allele was reported to be the
allele with the higher enzyme activity [18].
A49T, V89L and TA repeat polymorphisms could be asso-
ciated with risk of breast cancer. To our knowledge,
however, there have been no studies on the potential
association between SRD5A2 gene polymorphisms and
breast cancer risk except for one study of the TA repeat
polymorphism, which demonstrated no significant differ-
ence in the genotype distribution between 141 cases and
70 controls [19]. However, several studies for prostate
cancer risk have been reported [17,18,20–26]. Two
reports have been published by the same research group
in Italy concerning roles in breast cancer prognosis, one
regarding the TA repeats [19] and the other regarding the
V89L polymorphism [27].
The present study aims to examine the associations
between three polymorphisms of SRD5A2 and breast
cancer risk for Japanese women using a prevalent
case–control study conducted at Aichi Cancer Center.
Materials and methods
Study population
The cases were female breast cancer patients visited at
Aichi Cancer Center Hospital [28]. Between March 1999
and April 2000, 247 breast cancer cases were inter-
viewed, and 243 were enrolled. Two patients refused to
provide a blood sample after enrollment, and two blood
samples were not stored. Among the 239 blood samples,
two samples of extracted DNA had concentrations too low
to be genotyped. The remaining 237 samples were used
in the present study. The pathology of breast tumors was
examined for 204 cases at Aichi Cancer Center Hospital,
and for 33 cases at other hospitals.
The controls were 187 female cancer-free outpatients,
mainly presenting at the clinics for gastroenterology,
breast surgery, and gynecology of Aichi Cancer Center
Hospital. They were also invited during March 1999 and
April 2000. One serum sample was not stored, and one
had too low a DNA concentration to be genotyped. Only
185 controls were therefore available.
All participants were given a self-administrated ques-
tionnaire. Information was requested on demography,
family history of breast cancer (mother and/or sisters),
and food intake before the appearance of symptoms.
Interviewers checked all written responses to ensure
that there were no unanswered questions at the time of
questionnaire collection.
Genetic analyses
PCR amplification of the A49T polymorphism was con-
ducted by a PCR with confronting two-pair primers
method [29], using the following primers: 5′-GCG GAC
ACG GGT GGC GTC-3′, 5′-GAA CCA GGC GGC
GCG GGT-3′, 5′-GCG GCT ACC CGC CTG CCA G-3′,
and 5′-CGC CGG GAG CAG GGC AGT-3′. Aliquots of
30–100 ng genomic DNA were mixed with 25 µl reaction
liquid containing 0.18 mmol/l dNTPs, 12.5 pmol each
primer, 0.5 units AmpliTaq Gold, and 2.5 µl GeneAmp
10 × PCR buffer with 15 mmol/l MgCl2 (Perkin-Elmer
Corporation, Foster City, CA, USA). Amplification conditions
were set as follows: a 10-min initial denaturation at 95°C,Page 3 of 7
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followed by 30 cycles at 95°C for 1 min denaturation,
64°C for 1 min annealing and 72°C for 1 min extension,
and the final extension was at 72°C for 5 min. Genotyping
was 403 and 209 bp for the alanine (A) allele, and 430
and 257 bp for the threonine (T) allele.
V89L polymorphisms were genotyped by a PCR-restriction
fragment length polymorphism method described by
Yamada et al. [24].
Genotypes of the TA repeat polymorphism were deter-
mined using the primers 5′-GCT GAT GAA AAC TGT CAA
GCT-3′ and 5′-ACT CTA AGC AGA CAC CAC TCA G-3′,
with PCR conditions the same as for the A49T polymor-
phism except for annealing at 54°C. Amplified DNA was
129 bp for the TA(0) allele and 147 bp for the TA(9) allele.
Genotyping was confirmed for two samples of TA(0/0)
and TA(9/9) by DNA sequencing.
Statistical methods
The Stata 7.0 software package (STATA Corp., College
Station, TX, USA) was used to analyze the results, with
the Pearson chi-square test employed to compare the dis-
tribution of characteristics between cases and controls.
ORs and 95% CIs were estimated by unconditional logis-
tic regression analysis.
Results
Characteristics of the study subjects
Our research included 237 female breast cancer cases
and 185 female controls. The means and the standard
deviations of age were 50.5 ± 8.5 years for cases and
52.9 ± 10.2 years for controls. The other characteristics of
cases and controls are summarized in Table 1. No differ-
ences in the distributions were observed between cases
and controls, except for the menopause state (women
without menstruation caused by medication or surgery
were included in the premenopause group if aged
<50 years) and family history of breast cancer (mother
and/or sisters).
Distributions of SRD5A2 polymorphisms and crude ORs
Table 2 presents the distributions of SRD5A2 polymor-
phisms. All subjects were found to have the A/A genotype
for A49T polymorphism.
Two cases and two controls could not be genotyped for
the V89L polymorphism. Frequencies of the L/L, V/L and
V/V genotypes were 21.7, 52.3, and 26.0% for cases, and
32.8, 43.2, and 24.0% for controls, respectively. Com-
pared with the V/V genotype, the L/L genotype demon-
strated a marginally significant OR of 0.61 (95% CI =
0.36–1.05). Table 3 presents the results of the subgroup
analysis. Although not significant, women with the L/L
genotype had a reduced risk in any subgroup except
those with a family history of breast cancer. There was no
difference in the OR between premenopausal women and
postmenopausal women. The significance of OR was
marginal among the body mass index (BMI) <22 group.
The present study found only two types of TA repeat
alleles: TA(0) and TA(9). The frequencies of the TA(0/0),
TA(0/9) and TA(9/9) genotypes were 75.9, 22.8, and
1.3% for cases, and 75.1, 22.7, and 2.2% for controls,
respectively. No reduction in the OR was found for the
TA(0/9) genotype, and women with genotype TA(9/9)
were too few to be evaluated (Table 2). The difference in
the OR was not observed between premenopausal
women (OR = 0.85, 95% CI = 0.43–1.66 for TA(0/9) +
TA(9/9) relative to TA(0/0)) and postmenopausal women
(OR = 1.09, 95% CI = 0.59–2.01). Accordingly, no sub-
group analysis was conducted.
SRD5A2 polymorphisms and risk factors
The associations of the polymorphism genotypes with age
at menarche, age at menopause, and BMI were examined
among the present controls. No associations were
Available online http://breast-cancer-research.com/content/4/4/R8
Table 1
Characteristics of the study subjects
Cases Controls 
Characteristic (n = 237) (n = 185) Chi-square P value
Age *
< 45 years 53 38
≥ 45 years 184 147 0.20 0.65
Body mass index
< 22 kg/m2 126 99
≥ 22 kg/m2 111 86 0.005 0.94
Age at menarche
< 14 years 113 92
≥ 14 years 124 93 0.17 0.68
Age at first birth
< 25 years 96 67
≥ 25 years 112 98
No birth 29 20 1.36 0.51
Number of births
< 2 56 43
≥ 2 181 142 0.009 0.93
Menopause state
Premenopause 134 71
Postmenopause 103 114 13.72 < 0.001
Alcohol
< 1 day/week 184 148
≥ 1 day/week 53 37 0.35 0.56
Smoking
Noncurrent 211 169
Current 26 16 0.63 0.43
Family history of breast cancer (mother and /or sisters)
No 207 173
Yes 30 12 4.42 0.04
* Age at diagnosis for cases and at study enrollment for controls.Breast Cancer Research    Vol 4 No 4 Yang et al.
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Table 2
Genotype distributions of A49T, V89L and TA repeat polymorphisms
Genotype Cases Controls Crude odds ratio 95% Confidence interval
A49T
A/A 237 (100) 185 (100) – –
V89L
V/V 61 (26.0) 44 (24.0) 1.00 Reference
V/L 123 (52.3) 79 (43.2) 1.12 0.70–1.81
L/L 51 (21.7) 60 (32.8) 0.61 0.36–1.05
V/L+L/L 174 (75.0) 139 (76.0) 0.90 0.58–1.41
TA repeats
0/0 180 (75.9) 139 (75.1) 1.00 Reference
0/9 54 (22.8) 42 (22.7) 0.99 0.63–1.57
9/9 3 (1.3) 4 (2.2) 0.58 0.13–2.63
0/9 + 9/9 57 (24.1) 46 (24.9) 0.96 0.61–1.50
Percentages are shown in parentheses.
Table 3
Crude odds ratios and 95% confidence intervals for V89L polymorphism by subgroup
Genotype
Subgroup V/V V/L L/L V/L + L/L
Age at diagnosis
< 45 years 1.00 0.71 (0.25–1.99) 0.45 (0.14–1.52) 0.62 (0.23–1.64)
≥ 45 years 1.00 1.28 (0.74–2.21) 0.70 (0.37–1.22) 1.00 (0.61–1.67)
Body mass index
< 22 kg/m2 1.00 1.06 (0.55–2.06) 0.48 (0.23–1.00) 0.80 (0.43–1.48)
≥ 22 kg/m2 1.00 1.19 (0.59–2.38) 0.82 (0.37–1.79) 1.04 (0.54–1.99)
Age at menarche
< 14 years 1.00 1.36 (0.67–2.75) 0.76 (0.35–1.66) 1.10 (0.56–2.13)
≥ 14 years 1.00 0.97 (0.50–1.88) 0.51 (0.24–1.09) 0.78 (0.42–1.43)
Age at first birth
< 25 years 1.00 1.08 (0.49–2.38) 0.60 (0.25–1.44) 0.87 (0.42–1.82)
≥ 25 years 1.00 1.24 (0.64–2.42) 0.67 (0.31–1.42) 0.99 (0.53–1.85)
No birth 1.00 0.78 (0.18–3.36) 0.43 (0.08–2.17) 0.63 (0.16–2.46)
Number of births
< 2 1.00 0.81 (0.27–2.38) 0.40 (0.12–1.32) 0.63 (0.23–1.74)
≥ 2 1.00 1.22 (0.71–2.08) 0.68 (0.37–1.25) 0.99 (0.60–1.63)
Menopause state
Premenopause 1.00 1.01 (0.49–2.09) 0.67 (0.29–1.52) 0.88 (0.45–1.74)
Postmenopause 1.00 1.16 (0.60–2.23) 0.56 (0.27–1.18) 0.88 (0.48–1.62)
Alcohol
< 1 day/week 1.00 1.19 (0.69–2.05) 0.66 (0.36–1.22) 0.97 (0.58–1.60)
≥ 1 day/week 1.00 0.94 (0.33–2.65) 0.48 (0.15–1.50) 0.72 (0.28–1.88)
Smoking
Noncurrent 1.00 1.29 (0.78–2.13) 0.64 (0.36–1.12) 1.00 (0.63–1.59)
Current 1.00 0.16 (0.02–1.51) 0.20 (0.02–2.18) 0.17 (0.02–1.55)
Family history of breast cancer
No 1.00 1.22 (0.73–2.03) 0.59 (0.33–1.05) 0.95 (0.59–1.52)
Yes 1.00 0.73 (0.15–3.50) 1.09 (0.19–6.20) 0.86 (0.21–3.54)observed with mean ages at menarche and at menopause.
Mean age at menarche (standard deviation) was 13.6 years
(1.5 years) for the V/V genotype, 13.7 years (1.8 years) for
the V/L genotype, 13.7 years (1.8 years) for the L/L geno-
type, 13.7 years (1.8 years) for the TA(0/0) genotype,
13.7 years (1.6 years) for the TA(0/9) genotype, and
13.5 years (2.4 years) for the TA(9/9) genotype. Among
control women with natural menopause, the mean age at
menopause (standard deviation) was 50.5 years (2.7 years)
for the V/V genotype, 50.1 years (3.8 years) for the V/L
genotype, 50.1 years (3.6 years) for the L/L genotype,
50.8 years (3.7 years) for the TA(0/0) genotype, 49.6 years
(2.6 years) for the TA(0/9) genotype, and there were no
postmenopausal controls with the TA(9/9) genotype.
The mean BMI (standard deviation) was also similar among
the subgroups according to genotype except for four
women with the TA(9/9) genotype: 22.5 (3.1), 22.2 (3.0),
and 21.9 (2.9) for the V89L polymorphism, and 22.3 (3.0),
22.1 (3.1), and 19.7 (0.4) for the TA repeat polymorphism,
respectively.
Relationship between V89L and TA repeat genotypes
The combined genotype frequency between TA repeat
and V89L polymorphisms was also examined (Table 4).
The V/V genotype among controls was 15.2% (21/138)
for the TA(0/0) genotype, 46.3% (19/41) for the TA(0/9)
genotype, and 100% (4/4) for the TA(9/9) genotype,
while that among cases was 21.9% (39/178), 35.2%
(19/54), and 100% (3/3), respectively. Fisher’s exact test
for 3 × 3 tables showed a significant association between
the two genotype distributions both among cases and
controls (P < 0.001).
ORs for the combination of V89L and TA repeat
polymorphisms
Table 5 presents the ORs for each combination of the two
polymorphisms relative to women with the V/V and
TA(0/0) genotypes, who had the highest risk of breast
cancer. The combination of L/L and TA(0/0) had a signifi-
cantly decreased risk, with an OR of 0.46 (95% CI =
0.24–0.88), and the combination of V/V and TA(9/9)
showed the lowest, but insignificant, OR. The other three
combinations indicated an intermediately reduced risk.
Discussion
Although one study reported that the effect of testos-
terone was cancelled by the adjustment of the estradiol
level [30], several studies have provided epidemiological
evidence that the serum level of testosterone is associ-
ated with the risk of breast cancer [2,4–6]. On the con-
trary, experimental data propose evidence that androgens
are protective against breast cancer [7–10]. The present
polymorphism study added the finding that the SRD5A2
genotypes with a lower enzyme activity may reduce the
breast cancer risk.
Available online http://breast-cancer-research.com/content/4/4/R8
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Table 4
Genotype distributions of V89L and TA repeat polymorphisms
V89L genotype (%) Fisher’s 
exact 
TA genotype V/V V/L L/L Total P value
Cases
TA(0/0) 39 (16.6) 88 (37.4) 51 (21.7) 178 (75.7)
TA(0/9) 19 (8.1) 35 (14.9) 0 (0.0) 54 (23.0)
TA(9/9) 3 (1.3) 0 (0.0) 0 (0.0) 3 (1.3)
Total 61 (26.0) 123 (52.3) 51 (21.7) 235 (100.0) < 0.001
Controls
TA(0/0) 21 (11.5) 57 (31.2) 60 (32.8) 138 (75.4)
TA(0/9) 19 (10.4) 22 (12.0) 0 (0.0) 41 (22.4)
TA(9/9) 4 (2.2) 0 (0.0) 0 (0.0) 4 (2.2)
Total 44 (24.0) 79 (43.2) 60 (32.8) 183 (100.0) < 0.001
Percentages are shown in parentheses.
Table 5
Odds ratios and 95% confidence intervals for combinations of V89L and TA repeat polymorphisms
Combined genotype Odds ratio (95% confidence interval)
V89L TA repeat Cases (n = 235) Controls (n = 185) Crude Adjusted*
V/V 0/0 39 21 1.00 1.00
V/L 0/0 88 57 0.83 (0.44–1.56) 0.78 (0.41–1.49)
L/L 0/0 51 60 0.46 (0.24–0.88) 0.45 (0.23–0.87)
V/V 0/9 19 19 0.54 (0.24–1.23) 0.49 (0.21–1.15)
V/L 0/9 35 22 0.86 (0.40–1.82) 0.91 (0.42–1.96)
V/V 9/9 3 4 0.40 (0.08–1.98) 0.34 (0.07–1.79)
Data presented as odds ratio (95% confidence interval). * Adjusting for family history of breast cancer and menopause state.Since the difference in enzyme activity by the genotypes
was explained in the Introduction, the potential impact on
hormone concentrations should be discussed. Although
hormone levels are determined by activities of several
enzymes and the influence of the genotypes may differ
between females and males, the V89L L/L genotype with
low activity was found in Chinese men to be associated
with a significantly higher concentration of testosterone,
but not with dihydrotestosterone concentration [17]. In
British men, the genotype had a significant association
with a lower serum level of testosterone and free testos-
terone [15]. The present study suggests that the L/L
genotype might decrease the risk for breast cancer, espe-
cially among women with BMI <22 (Table 3). The L/L
genotype was reported to be more frequent in Asian men
(21.6%, n = 102) than in Caucasian men (4.1%, n = 49)
and African-American men (3.2%, n = 95) [14], which may
partly explain the low incidence in breast cancer among
Asian women.
Of the TA repeat alleles, only TA(0) and TA(9) were
observed in our subjects. The present genotype frequency
for Japanese women was similar to those in Italy (n = 70;
79% for TA(0/0), 17% for TA(0/9), and 4% for TA(9/9))
[19], in the United States (n = 802; 75% for TA(0/0), 22%
for TA(0/9), and 2% for TA(9/9)) [20], and in China
(n = 304; 82% for TA(0/0), 17% for TA(0/9), and 1% for
TA(9/9)) [17].
The present study demonstrated a tendency for risk
reduction with the TA(9/9) genotype compared with the
TA(0/0) genotype (Table 2). In a small-sized study with
141 cases and 70 controls in Italy, there was no signifi-
cant association between the TA repeat polymorphism
and risk of breast cancer [19], while the TA(0/9) or the
TA(9/9) genotype demonstrates a reduction in the risk for
relapse (P = 0.043). The combination analysis of TA
repeat and V89L polymorphisms suggested that women
with the TA(0/0) and V/V genotypes had the highest risk
for breast cancer (Table 5). This is a plausible finding bio-
logically, because the genotype is regarded to have the
highest enzyme activity. There are no studies that examine
the joint effect on prostate cancer.
The lack of alanine to threonine substitution in SRD5A2
codon 49 in our subjects is in accordance with a previous
study in Japan [24] and another in China [17], suggesting
that the T allele may not exist among Asians. The reported
frequency of the T allele was 1.0% of 522 alleles for
African-American men and 2.3% of 400 alleles for His-
panic men [18]. In Finland, individuals with the T allele
were 5.8% (n = 588) for donated blood and cancer-free
autopsy samples [26]. The absence of the T allele among
Asians may indicate that the polymorphism occurred rela-
tively recently in comparison with V89L and TA repeat
polymorphisms. For examining the effects of V89L and TA
repeat polymorphisms, our subjects had an advantage in
that there was no need to consider the potential effect of
A49T as a confounder or a modifier.
The present study demonstrates that the TA(9) allele only
coexisted with the V allele (Table 4). The absence of the
TA(9/9)–L/L genotype indicated a strong linkage disequilib-
rium. Another study in Italy unearthed the same result [27].
Conclusions
The present study suggests an reduced risk of breast
cancer among women without the genotype combination
of SRD5A2 V/V and TA(0/0). An absence of the geno-
types necessitating the L–TA(9) haplotype indicated
linkage disequilibrium between V89L and TA repeat poly-
morphisms. There appears to be no substitution of alanine
to threonine in codon 49 among the Japanese. Since the
metabolic pathway of steroid hormones is complicatedly
regulated, activity of a single metabolic enzyme cannot
solely describe the risk of breast cancer. In addition, to
confirm the association observed in the present study, a
systematic approach taking account of potentially relating
polymorphisms is desirable in the near future.
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